Harel Insurance Investments & Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-54,425	Closed	-$7.43M	–	527
2024 Q4	$7.43M	Buy	54,425 +18,797	+53%	+$2.32M	0.12%	69
2024 Q3	$4.11M	Buy	35,628 +13,936	+64%	+$1.91M	0.07%	86
2024 Q2	$2.91M	Buy	+21,692	New	+$2.97M	0.05%	105
2019 Q2	–	Sell	-146	Closed	-$13K	–	511
2019 Q1	$13K	Sell	146 -135	-48%	-$11.3K	﹤0.01%	389
2018 Q4	$20K	Sell	281 -5	-2%	-$479	﹤0.01%	384
2018 Q3	$35K	Buy	286 +65	+29%	+$7.38K	﹤0.01%	381
2018 Q2	$22K	Buy	+221	New	+$19.8K	﹤0.01%	386

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services's NBIX Position: Q1 2025 in Review

Harel Insurance Investments & Financial Services sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 54,425 shares — an estimated $7.43M sold.

Harel Insurance Investments & Financial Services first reported a position in NBIX in Q2 2018 and held it in 7 quarters. The position peaked at $7.43M in Q4 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

Harel Insurance Investments & Financial Services reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
Harel Insurance Investments & Financial Services sold 54,425 Neurocrine Biosciences shares in Q1 2025, an estimated $7.43M.
Harel Insurance Investments & Financial Services first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 7 quarters.
Harel Insurance Investments & Financial Services's Neurocrine Biosciences position peaked at $7.43M in Q4 2024.
587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q1 2025, filed 29 Apr 2025.